亚临床巨细胞动脉炎增加风湿性多肌痛复发风险
该研究纳入150例符合2012年EULAR/ACR风湿性多肌痛临时分类标准、无巨细胞动脉炎症状的患者,按超声分为单纯风湿性多肌痛组和风湿性多肌痛合并亚临床巨细胞动脉炎组,随访中位22个月。合并亚临床巨细胞动脉炎组复发率显著高于单纯组(62% vs 16%,p<0.001),且复发者前3个月泼尼松减量更快。
要点
- 风湿性多肌痛合并亚临床巨细胞动脉炎患者2年随访复发率62%,显著高于单纯风湿性多肌痛组的16%。
- 亚临床巨细胞动脉炎组中,复发者前3个月泼尼松减量更快,第3个月日均剂量10.0±5.2 mg vs 未复发者15.2±7.9 mg(p<0.001)。
- 复发与非复发亚临床巨细胞动脉炎患者在年龄、性别、C反应蛋白和红细胞沉降率方面无差异。
核心结论
- 风湿性多肌痛合并亚临床巨细胞动脉炎患者2年随访期间复发次数显著高于单纯风湿性多肌痛患者。
- 较低的起始剂量和前3个月快速糖皮质激素减量是复发的危险因素。
研究设计与样本
- 研究纳入150例符合2012年EULAR/ACR风湿性多肌痛临时分类标准、无巨细胞动脉炎症状并常规随访2年的风湿性多肌痛患者,按超声结果分为单纯风湿性多肌痛组和风湿性多肌痛合并亚临床巨细胞动脉炎组,比较两组复发、糖皮质激素使用和改善病情抗风湿药治疗等结局。
主要发现
- 共纳入150例风湿性多肌痛患者(50例合并亚临床巨细胞动脉炎),中位随访22个月(IQR 20-24)。
- 总体47例(31.3%)复发,亚临床巨细胞动脉炎组31例(62%),单纯风湿性多肌痛组16例(16%),p<0.001。
- 亚临床巨细胞动脉炎组中,复发与非复发患者泼尼松起始平均剂量分别为32.4±15.6 mg和35.5±12.1 mg,p=0.722。
- 亚临床巨细胞动脉炎组中,复发患者前3个月泼尼松减量更快,第3个月平均日剂量为10.0±5.2 mg,非复发患者为15.2±7.9 mg,p<0.001。
- 亚临床巨细胞动脉炎组中,复发与非复发患者在年龄、性别、C反应蛋白和红细胞沉降率方面无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the present study was to determine the clinical significance of subclinical giant cell arteritis (GCA) in polymyalgia rheumatica (PMR) and ascertain its optimal treatment approach. METHODS: Patients with PMR who fulfilled the 2012 European Alliance of Associations for Rheumatology/American College of Rheumatology Provisional Classification Criteria for PMR, did not have GCA symptoms and were routinely followed up for 2 years and were stratified into two groups, according to their ultrasound results: isolated PMR and PMR with subclinical GCA. The outcomes (relapses, glucocorticoid use and disease-modifying antirheumatic drug treatments) between groups were compared. RESULTS: We included 150 patients with PMR (50 with subclinical GCA) with a median (IQR) follow-up of 22 (20-24) months. Overall, 47 patients (31.3 %) had a relapse, 31 (62%) in the subclinical GCA group and 16 (16%) in the isolated PMR group (p<0.001). Among patients with subclinical GCA, no differences were found in the mean (SD) prednisone starting dosage between relapsed and non-relapsed patients (32.4±15.6 vs 35.5±12.1 mg, respectively, p=0.722). Patients with subclinical GCA who relapsed had a faster prednisone dose tapering in the first 3 months compared with the non-relapsed patients, with a mean dose at the third month of 10.0±5.2 versus 15.2±7.9 mg daily (p<0.001). No differences were found between relapsing and non-relapsed patients with subclinical GCA regarding age, sex, C reactive protein and erythrocyte sedimentation rate. CONCLUSIONS: Patients with PMR and subclinical GCA had a significantly higher number of relapses during a 2-year follow-up than patients with isolated PMR. Lower starting doses and rapid glucocorticoid tapering in the first 3 months emerged as risk factors for relapse.
引用
- De Miguel E, Karalilova R, Macchioni P, et al. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica. Ann Rheum Dis. 2024. PMID: 37932008. doi:10.1136/ard-2023-224768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。